Heart failure is a leading cause of mortality worldwide. Specified diagnostic approach
for heart failure remains a serious dilemma for scientist and physicians. It’s the
need of time to develop the cost effective specified diagnostic strategies that may
predict the heart damage at pre and post ischemic stage. Therefore, the current study
aimed to develop assay based on Endothelin-1 as the diagnostic marker for periodic
heart failure. Endothelin-1 is a potent neuro-hormone is involved in the vasoconstriction
after binding to respective G-coupled receptor and mediated cardiac signaling. In
preliminary studies, we have worked on elucidating the role of Endothelin-1 in different
experimental models of cardiac disorders. Diabetes induced cardiac hypertrophy model
and cardiac ischemia models were established and confirmed by assessing morphological
parameters, heart weight/body weight, heart weight/tibia length, cell surface area,
histopathological examination and molecular cardiac biomarkers. Lipid peroxidation,
oxidative and antioxidative profile analysis were also performed to delineate the
pathways involved in cardiovascular signaling. The expression of endothelin- 1 was
assessed in invitro and invivo models both at transcriptional and translational level.
This diagnostic model may serve as potential molecular indicator of heart health.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Metabolism - Clinical and ExperimentalAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect